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1. INTRODUCTION 
Immunization remains the most cost effective method of prevention of infectious 
diseases over the past few decades (Duclos, Okwo-Bele, Gacic-Dobo, & Cherian, 
2009). Immunization has also accounted for the eradication of smallpox (Birn, 
2011), and elimination of polio in most countries. This has led to an intensive 
effort to deploy the strategy of immunization in the control and eradication of 
infectious diseases.  Consequently, the importance of clinical trials to test the 
safety, immunogenicity, efficacy, tolerability, appropriate dosing schedule and 
effectiveness for vaccines cannot be over emphasised as more vaccines are being 
developed against various pathogens.   
As the major burden of infectious diseases occurs in the resource 
constrained countries, it is essential that these vaccines are tested in these regions 
with the same rigor as anywhere else. To obtain a licence for the use of a vaccine 
within a certain region however, the product needs to be well tolerated and 
proven to be effective in that particular setting. Thus, late stage clinical trials of 
relevant vaccines are increasingly being conducted in sub-Saharan Africa 
(Craddock, 2012; Rehnquist, 2001).  Recent increases in the number of early phase 
clinical trials being conducted in developing countries have brought a set of 
additional factors that pose considerable challenges to planning and 
implementation of clinical trials in these settings (Beurret, Hamidi, & 
Kreeftenberg, 2012; Louisa, Takeuchi, Setiabudy, & Nafrialdi, 2012).  These trials 
create opportunities for collaboration between the pharmaceutical and biotech 
companies, investigators, sponsors, clinical trial monitors, regulatory authorities 
and the study communities. Investigators often play a central role in filling the 
gap between the sponsors and most of the partners involved in the evaluation of 
these investigational products including the community. These interactions are 
often quite complex, with several benefits and challenges coming into play.  This 
	
	
complexity could undermine the desired objectives when the major players in the 
partnership or collaboration have little understanding of the prevailing 
circumstances in the sub region.  Understanding and discussing these factors 
may help with projections of financial, time and labour costs as well as the 
development of better working relationships between the key players. This 
chapter seeks to highlight the impact and some of the challenges and innovative 
ways of conducting early and late stage clinical research within Africa, with a 
view of stimulating interest in this area and charting the process of making the 
sub-Saharan Africa region a future hub of clinical trials. 
 
 
2. IMPACT OF VACCINE TRIALS ON THE 
COMMUNITY 
Vaccine trials in Africa can be perceived to have varying effects on the 
community where research is carried out.  These range from the direct benefit to 
the participant who encounters a new vaccine which he/she may not otherwise 
have come into contact with, to the provision of better health care for the study 
population to potential risks that can be encountered especially where a vaccine 
has not been well evaluated in the pre-clinical and phase I stages (Idoko, 
Kochhar, Agbenyega, Ogutu, & Ota, 2013). 
 
 
Box 1: Impact of Vaccine Trials: 
• Potential for protection against disease 
• Accelerated vaccine introduction into the 
community 
• Health care and capacity building 
• Health awareness 
• Infrastructure development 
• Employment opportunities 
• Community engagement 
 
  
2.1 Positive Impact of Vaccine Trials:  
	
	
 
2.1.1 Potential Protection Against Disease: 
A recipient of an investigational product during the vaccine trial has the benefit 
of being protected if such a product is found to be efficacious. Since there is 
usually a lag time between the clinical development and ultimate registration of 
a product leading to its roll out through a national policy and program, such an 
individual will have protective immunity well ahead of the community. In some 
instances, there is also the extended benefit to the community of the effect of herd 
immunity especially when large scale trials (phase IIIB or phase IV) have been 
conducted on large numbers of participants in a given community. This may 
have contributed to the decline in all cause mortality among infants following the 
large Pneumococcal Vaccine trial in The Gambia (Cutts et al., 2005), and 
insecticide treated bed nets (ITNs) trial in Kenya (Snow et al., 1999). However, 
the lag period in the uptake of new interventions can be mitigated by earlier 
sensitization of the target stakeholders during the product development phase. 
This will allow for cost effectiveness analysis, health system preparation, 
resource mobilization and human capacity development ensuring health system 
optimization ahead of time. 
The reverse is however also true as if the vaccine is found to have 
significant deleterious effects or not protective; the study community bears the 
brunt.  For instance, the use of thalidomide as an antiemetic in pregnant women 
in the 1960s led to teratogenic effects in hundreds of children as this drug had not 
been well researched for this indication (Miller & Stromland, 2011). A recent 
drug trial in France also left 1 man dead and several others with neurologic 
disability after they received increasing doses of a drug aimed at treating anxiety 
and motor disorders associated with Parkinson’s disease, and chronic pain in 
people with cancer and other conditions(Butler & Callaway, 2016). The same 
would apply for poorly evaluated vaccines in the early stages of development. 
There have also been a number of vaccine trials that have shown no protective 
effect despite being safe such as SPf 66 (Nosten et al., 1996) MSP1 and ME-TRAP 
(Bejon et al., 2006; Ogutu et al., 2009). However, these trials for vaccines which 
proved ineffective in protecting against the diseases for which they were 
designed have been major learning steps in vaccine development in resource 
constrained settings. 
 
2.1.2 Accelerated Vaccine Introduction Into the Community: 
Communities who take part in vaccine trials usually have the benefit of 
having such vaccines introduced first or at least early into their vaccination 
programme ("Ethical issues facing medical research in developing countries. 
Gambia Government/Medical Research Council Joint Ethical Committee," 1998; 
Kremer, 2001; Shapiro HT, 2001).There is often an agreement between the 
	
	
sponsors and vaccine producers and the government of countries where these 
clinical trials are conducted to provide these vaccines as soon as feasible at no or 
reduced cost for an agreed period of time. For instance, a large number of vaccine 
trials have been conducted in The Gambia including hepatitis B, pneumococcal 
conjugate vaccines and Haemophilus influenza type B. Following the proven 
efficacy of these vaccines, they were incorporated into the country’s Expanded 
Programme of Immunization (EPI) schedule. Consequently, The Gambia has one 
of the most robust and comprehensive childhood vaccine programmes of all the 
countries within the West African sub-region and Africa as a whole 
(UNICEF/WHO, 2011). The protection against a larger number of pathogens 
through these vaccines will certainly impact positively on the entire populace 
reducing morbidity and mortality.  
 
2.1.3 Health Care and Capacity Building for the Community: 
Conduct of clinical trials often comes with establishment or strengthening 
of research facilities in a given region. This is usually also associated with the 
deployment of trained health personnel. For instance, there have been clinical 
trials with a team of clinicians taking place in health centres with no resident 
doctor. Such doctors provide some skilled services to the centre in addition to 
their working on the clinical trial. The benefit is that the study community has a 
greater chance to encounter highly trained health care professionals able to 
attend to the health care needs of the population. There is usually also the direct 
benefit of free health care from the clinical team for the participant and their 
immediate relatives. The interaction with the clinical trial clinicians also results in 
better training of local health care personnel with resultant improved care to the 
local population (Arenas-Lopez et al., 2011; Ogutu, Baiden, Diallo, Smith, & 
Binka, 2010; Tinto et al., 2014). In some settings the tendency of locally available 
trained staff preferring to take up jobs in the urban often better paying 
government settings is now being reversed. More professionals than previously 
now move to often rural research sites for the purposes of training and exposure 
to other highly trained trial professionals (Tinto et al., 2014). 
 
2.1.4 Health Awareness in the Community: 
The presence of research teams and activities in the community help to 
create increased awareness of public health needs in general. This may be in the 
form of health talks in the pre- vaccination clinics, information contained in 
information sheets for specific trials or through specific interventions. For 
instance, in a recent trial to test the safety and immunogenicity of a conjugate 
vaccine, it was noted during the course of follow up of the children enrolled in 
the study from soon after birth that they tended to develop malnutrition around 
the age of one year. This was likely as a result of defects in the weaning style or 
	
	
feeds, an activity that occurs commonly at this period.  This led to the 
intervention of the Data Safety Monitoring Board which recommended an 
intervention, including health education and demonstrations of how to use 
locally available food items to prepare healthy weaning meals. Subsequently, the 
prevalence of malnutrition among this cohort of study participants declined, 
which was a good lesson for subsequent implementation. The improved access to 
health care results in improved child survival with reduced childhood mortality 
in intervention studies compared to the rest of the community. This particular 
intervention had a spill over effect to the community as other caregivers not 
involved in the main study routinely participated in these education and 
demonstration sessions. This is more evident in malaria studies where the close 
follow up results in disappearance of severe disease making it difficult for such 
disease to be studied as an outcome measure (Steketee & Campbell, 2010). 
 
 2.1.5 Infrastructure Development and Capacity Building: 
Most trials require the use of equipment which may not otherwise be 
available in the community/research institute especially in settings that were not 
initially designed for clinical trials (Kilama, Chilengi, & Wanga, 2007; Louisa et 
al., 2012). For instance the pneumococcal vaccine trial in a province in The 
Gambia required the acquisition of a high quality digital X-Ray machine, and a 
microbiology laboratory to enable the trials to be conducted to the required 
standards. Along with such upgrades in facilities often come staff training on the 
use and maintenance of new equipment, and thus capacity building for that 
community. Such an upgrade in infrastructure and staff capacity strengthens the 
research institutes, which makes them better contenders for future research 
funding. This is especially so as such facilities will need to meet Good Clinical 
Practice (GCP) and Good Clinical Laboratory Practice (GCLP) standards. This 
has been also the case of RTS,S malaria vaccine trials where all the centres 
involved acquired digital X-ray machines and bacteriology laboratories (Tinto et 
al., 2014). 
Furthermore, some new clinical trials require erecting new buildings or 
renovating existing ones including construction of sanitary facilities. These 
buildings plus the state of the art equipment and laboratories remain within the 
research centres or the government health facilities on completion of the trial, 
thus contributing to infrastructure development and improvement of the 
standard of health care and research capacity within the community.  
 
2.1.6 Provision of Employment Opportunities: 
Regulatory authorities require clinical trials to be conducted to the highest 
standard and for the quality of results to be robust and trust worthy. Therefore 
clinical trials are rigorous and require a large team of staff for the various tasks 
	
	
involved. In resource-constrained sub-Saharan Africa with high unemployment 
rates vaccine trials provide opportunities for employment for the community at 
various levels such as doctors, nurses, field workers, data clerks, administrators, 
financial managers, logisticians, drivers, cleaners and other support staff. 
However, the sustenance and retention of these skilled workers is not easy in 
circumstances where the trials are not conducted in settings with the framework 
of continuity after the specific studies are over. This is key for development of the 
region as a hub for clinical trials in the future as there is need for ready platforms 
that can initiate and execute studies on short notice with minimal lag period. This 
calls for a concerted effort by all partners involved in clinical trials to nurture the 
varied clinical research careers that are critical for product development.   
    
2.1.7 Community Engagement: 
The presence of research institutes in the community often leads to 
engagement with the community which may go beyond the direct impact or 
benefit from individual research projects. This leads to a generally more 
enlightened populace as it relates to issues of health. Schools and other 
institutions are likely to engage in field trips to these institutions resulting in 
more interest in the sciences that allow the institution to be effectively run. A 
number of institutes offer foundation degrees or training courses which create 
educational opportunities where there may previously have been none including 
platforms for MSc, PhD and post doctoral projects. All these may ultimately lead 
to better community engagement with the sciences and overall capacity 
development within the community.  
 
	
	
                
      
              Figure 1: Community engagement: a crucial part of vaccine trials.  
Photo courtesy Abdoulie Cham MRC Unit, The Gambia. 
 
2.2 Challenges of Vaccine Trials 
As in every operation, several challenges are encountered in the conduct of 
clinical trials in sub-Saharan Africa. Some of these are due to the unique 
peculiarities of the region while others are more generic. These challenges if not 
well managed, may affect the credibility of clinical trial data obtained in such 
regions (Idoko et al., 2013). This section seeks to highlight some pressing and 
often neglected challenges as a possible starting point to developing a co-
ordinated approach to dealing with some of these problems. 
 
 
 
 
 
 
	
	
     Box 2: Challenges of Vaccine Trials: 
• Community dependence 
• Brain drain/circulation 
• Waste disposal 
• Budget constrains 
• Obtaining informed consent 
• Follow-up and protocol adherence 
• Stringent enrolment criteria 
• Use of diary cards 
• Culture and belief systems 
• Monitoring and communication 
• Institutional understanding of trial needs 
• Use of electronic data collection methods 
• Vaccine/sample storage/transport conditions 
• Absence of local reference values 
• Supplementary EPI campaigns 
• Use of prophylactic or post vaccination antipyretics 
• Infant weight faltering 
• Investigator professional development. 
 
 
2.2.1 Community Dependence: 
One of the major drawbacks of clinical research in general, and vaccine 
research in particular is the tendency for the communities to begin to rely on the 
research institute or project for their health care needs. This is more so when such 
research is conducted in largely donor driven economies. The tendency is for the 
community to see the research institute as another donor agency there to meet a 
certain need (Idoko et al., 2013). The situation tends to be by exacerbated by low 
	
	
literacy levels and lack community understanding of the difference between 
research and development projects. As a result, the time-bound nature of studies 
may not be clearly understood by the community, who then expect continued 
care long after funds for the study are no longer available. The health facilities 
and government also begin to rely on such services and may fail to plan for 
appropriate staff and adequate consumable stocks. The result of this is a rapid 
decline in the key performance indicators of health facilities that were doing well 
during the active phase of a clinical trial. As patients are unlikely to know about 
such a change in quality of care, an increase in the morbidity and mortality might 
occur.  Clear communication which starts prior to study enrolment and continues 
throughout the course of a trial is crucial. Such timelines and budget limitations 
need to also be emphasized at community meetings and other community 
engagement activities. Trial teams need to also ensure that where feasible they 
strengthen the capacity of local health teams to continue to provide optimal care 
beyond the life span of the trials. 
 
2.2.2 Disposal of Waste: 
A lot of waste could be produced by some clinical trials. These need to be 
disposed of appropriately as a lot of these substances may be biologically 
hazardous. However, in resource-constrained settings with weak regulation or 
vigilance, there is a tendency not to adhere to the rules and universal precautions 
in a bid to cut cost. For instance in one trial it was noted that study staff chose not 
to adhere to colour coding required for biohazard waste disposal bags as they 
temporarily run out of these (personal communication). This puts at risk the 
individual responsible for disposing this waste and possibly others in the 
community. This risk may not have been encountered in the absence of clinical 
trial activity in that setting. This is worsened by the high cost of establishing an 
optimal waste disposal system that can often not be borne by a single clinical trial 
however large. Research sites need to follow international and local regulations 
as available in the course of waste disposal and training and re-training on these 
issues is essential. This calls for a concerted effort by the governments, 
communities and researchers to put up waste disposal facilities for the safety of 
the society. 
  
2.2.3 Brain Drain/Circulation: 
Vaccine research especially when funded by pharmaceutical or biotech 
companies, public-private partnerships or international agencies often pays 
better than other available local sources of employment. Although this leads to 
transient increase in income and standard of living for the involved employees, it 
could in certain countries lead to a brain drain from government and other local 
private establishments to these centres. This can result in significant disharmony 
	
	
between the government and such research centres especially where these 
centres are not government owned. It is therefore necessary to devise means of 
mitigating such effects. Ensuring that the human resource involved in research 
activities also support the clinical care of the community through an agreed 
framework that supports the greater good of the community but not 
compromising standards. In some situations for instance, there are policies 
requiring that anyone who has held government employment within a certain 
time frame is not eligible for a job interview at the research establishment unless 
there is permission from the government. There is however a need to balance 
such policies as they may become discriminatory toward staff or prove to be 
detrimental to the usual capacity building/strengthening associated with 
working with such establishments. 
In other settings however, beneficial effects of such movements of staff 
have been noted.  The individuals involved in clinical trials are more willing to 
work in rural areas where many research sites are located due to better 
incentives. In these situations there is more of brain circulation than a drain, and 
this may indeed result in skilled care being better available where it is most 
needed. Governments where feasible, may need to make efforts to match these 
incentives, especially for their staff in rural areas. 
 
2.2.4 Budget: 
The area of clinical trials is still quite new in the region. As a result 
experience is often limited and investigators seem to have a tendency to overlook 
or under budget for the subtle needs which can arise during the trial. Some 
funding bodies do not want a miscellaneous budget line for incidentals in the 
budget. In addition, there is often a time lag between the time of budgeting and 
the actual initiation of the studies due to the period required to get regulatory 
approvals, import licences, review of product development milestones among 
others.  In most of the resource constrained countries the local currency is 
unstable and depreciation in value tends to put stress on the budget. This is 
worsened by the fact that almost all consumables used in clinical trials are 
imported from the global North to resource constrained countries. This makes 
the cost of these commodities prohibitive due to transportation cost, taxes and 
lag time in delivery (particularly important where items are perishable) and 
limited numbers of vendors deal in them. The foregoing makes them highly 
sensitive to currency fluctuations. 
These uncertainties need to be factored in when budgets are drawn up, 
and calls for the recruitment of competent finance managers to work with the 
study teams on the planning and execution of the study.  These should be 
financial managers with a good understanding of product development logistics 
which are also difficult competencies to come by in resource constrained settings. 
	
	
Sometimes the budget is already finalised before details of the protocol are 
agreed on. For instance the sponsor at initial contact with the site could suggest 
that a study will require 500 participants recruited over 6 months and each 
participant will be followed up for another 6 months. The cost of these will 
certainly differ if participants are visited in their homes every two weeks for the 6 
months and need blood samples collected for laboratory investigations compared 
to a less vigorous follow-up scheme. The latter with intensive home and clinic 
activities would require more staff and resources than the former, but this might 
not be considered if the intensity of activities are either not disclosed or 
anticipated at inception and planning of the budget. Moreover, a simple 
procedure such as visiting study participants in their homes could turn out to be 
more expensive than anticipated as the lack of addresses could make a team 
waste considerable time and resources in the process of accessing such 
participants. Therefore, the study team should have all the information about 
their study area mapped out such when negotiating for a project so they can 
justify their costs with respect to the requirements of the study. Having in place a 
health and demographic surveillance system enables the investigators to 
accurately estimate the number of potential study participants and where these 
participants may be located. Costs to maintain this surveillance system also need 
to be factored into the study budgets.  Unless these drivers of budget lines are 
known and well articulated they can result in unprecedented challenges. In 
circumstances when budgets are ‘per patient’ based, it calls for ingenuity in 
budgeting to cover all the cost areas antecedent to the study without setting up 
the study for cost overruns that may create study partnership fallout. A number 
of studies may also depend on climatic seasons and any slip in the timelines can 
have significant cost implications.    
These issues are further complicated by the fact that some funders are 
unwilling to either review or supplement the budget once agreements have been 
finalized. Taken together, there are several anticipated and unanticipated factors 
that could increase the cost of clinical trials in developing countries, and should 
be considered when preparing the budget. In addition, a degree of flexibility over 
budgets or addition of a reasonable proportion of the budget as incidentals 
would be useful, otherwise the quality and standards of the trial might be 
compromised. Therefore, good legal and project management support for the 
study team is needed to ensure their part of the agreement is well addressed for 
optimal and seamless conduct of the study. These all come at additional cost and 
need to be built in over time through a holistic partnership approach. 
2.2.5 Consent Process: 
The Informed Consent documents (ICD’s) and information sheet from 
sponsors of clinical trial are often very long, and could range from 10 to 20 pages 
containing a mixture of very technical and legal language (D, 2012; Preziosi et al., 
	
	
1997). Although there are some valid reasons for the contents of these lengthy 
ICF and subject information sheet, this poses a significant challenge when it 
comes to execution in resource constrained settings. Such lengthy information 
sheets will take a lot of time to explain to a participant with limited education, 
and will also not likely be comprehended to any reasonable degree. Moreover, 
having such a rigorous consenting process for a study that requires a large 
number of participants recruited per day will require more personnel. Inability to 
provide adequate staffing will lead to either a poor consenting process or huge 
waste of participants’ time, which discourages further participation. This aspect 
is often neglected with many sponsors insisting on lengthy information sheets 
without a commensurate budget for the staff required to administer them 
appropriately (Lang, 2011). 
The language of the subject information sheet is also often a challenge as 
most of the major local languages are spoken and do not have any known written 
form (Fairhead, Leach, & Small, 2006). Where written forms of these languages 
exist, they are not easily read even by the literate. Thus consent forms in many of 
these regions are currently accepted in English. This poses a wide range of 
challenges, as most of the rural population where illiteracy rates are high are 
unable to read English as well. This also means a study in such an environment 
will require extra capacity to explain in detail the contents of these forms to each 
participant. This can be resolved where the consent process continues during the 
study and at every visit an attempt is made to assess the understanding and 
more explanation provided. To obviate variation in explanation if the local 
language is not written or even where it is written but there is high illiteracy; the 
study team can prepare a video/audio tape of the consent so that every 
individual gets consistent information. The potential participants watch/listen to 
the tape in the presence of a study team member who is competent to answer the 
questions. Depending on the nature of the trial, the tape can be watched/listened 
to as a group. In addition, a multimedia informed consent tool has been 
developed in Gambian local languages to deliver study information to low 
literacy participants (Afolabi et al., 2014). This has also been used with good 
outcome in Western Kenya (personal communication). 
Another peculiarity in the consenting process in many resource 
constrained settings is the high prevalence of under-aged mothers. It is not 
uncommon to have mothers who are less than 18 years of age in these settings. 
Whether such a mother can provide consent for herself and for her child to 
participate in a vaccine trial is of considerable debate (Erulkar & Muthengi, 2009). 
This in most African settings is accepted and the participant allowed to give 
consent as a mature/emancipated minors. Some sponsors however have issues 
with this definition for legal reasons and may thus result in discrimination of this 
segment of the population. 
	
	
Another issue is that of the use of the term legal guardian. In many parts of 
Africa it is customary for young children to be left in the care of relatives to be 
weaned off breastfeeding or to allow  their parents to seek employment 
elsewhere within or outside the country (Ota, Idoko, Ogundare, & Afolabi, 2012). 
A number of orphaned children are also taken in by the relatives. These relatives 
often do not hold any legal document stating their relationship, but may be fully 
responsible for the child’s care. Whether such a “foster” parent without a legal 
document for his/her ward can give consent to have this child enrolled in a 
study is also debatable? This can raise issues as some studies have shown that 
non-parents are more likely to consent to have children participate in trials than 
parents (Nunez-Wallace, Gill, Harrison, Taylor, & Charles, 2010). What should 
obtain in such situations is not yet clearly defined in many settings leaving a gray 
area that needs to be explored further. This can be a grave issue when dealing 
with a disease such as HIV where a number of children may be orphaned and in 
the strict sense may not participate in studies due lack of a legal guardian. 
Sponsors are encouraged to accept what is culturally acceptable to the 
community and the local study team need to put mechanisms in place to ensure 
the rights of the children are not infringed and regulatory authorities accept the 
agreed practice. 
In populations with limited access to education there is often a need to 
appoint an impartial witness who is educated and understands the ICF and 
information sheet, to act as witness to the consent process for the participant who 
cannot read these documents. This often poses another challenge to consenting as 
men who are often the educated members of communities often delegate the 
responsibility of health care to the women and may thus be unwilling to come 
along to clinic visits with their wives or may be too busy providing for their 
families. This has in some instances led to study teams delegating a few educated 
members of communities to serve as impartial witnesses.  How impartial this 
process is may then become an issue especially where these individuals serve as 
witnesses over the long term. Study teams need to set up checks that help to keep 
this process as impartial as possible for instance setting limits to the number of 
participants an impartial witness may attest for. 
Some African cultures require that inheritance is through the mother and 
not the father’s lineage. Thus maternal uncles are responsible for the children of a 
woman. In this context, it would be required that this maternal uncle and not the 
father give consent for study participation. Communicating this to external 
sponsors may pose a challenge, especially when there is some cultural transition 
within the community as occurs in much of the developing world, and some 
subjects opt to have fathers give consent.  
Another issue is the lack of clarity on the age that assent should be 
obtained from study participants. For instance in a multisite study involving 3 
	
	
West African countries, age of assent was defined as 12 to 17, 13 to17  and 15 to 
17 years in three countries (Sow et al., 2011). While most countries will accept the 
teenage age group, this may not resonate with a sponsor from another country 
where the legal age of assent is 7 or 8 years like the USA. These call for tolerance 
and letting the local population requirements prevail. Despite this age limits in 
rural settings the requirement for assent from children may be perceived as 
eroding parental autonomy and this requires a well guided negotiated discussion 
with community leaders to help them understand the need for assent and avoid a 
negative perception of the research requirements. 
An area that has not received much attention and will likely become an 
area of intense debate is the evaluation of new products in persons who are 
mentally challenged. They are often left out in most of the early product 
development in the context of cultural beliefs and practices in reference to this 
segment of the population.  However as more products enter the development 
pipeline,, this will likely become a topic requiring attention.  
The area of the consenting process will remain an evolving area in clinical 
trials over time and legalities surrounding it should take into context cultural 
practices of the different communities. This is because individual autonomy 
operates in harmony with the wider community practices impacted by rapidly 
changing cultural practices due to technologically driven globalization. 
   
2.2.6 Follow-up and Adherence to Protocol: 
Adherence to the protocol is essential for the success of vaccine trials. This 
needs to be ensured among the participants and investigators alike, and failure to 
do this may impact significantly on research findings. Reasons for non-adherence 
vary from migration out of the study area to ill health, death, refusal to continue 
with the study, adverse events and dissatisfaction with the trial procedures or 
perceived benefits. In many communities within Africa populations are 
becoming increasingly mobile. It is not uncommon for school age or young 
children to move from rural to urban areas in pursuit of education. Another 
common scenario is that of the expectant mother moving to stay with relatives 
for a period and returning when her child is a few weeks or months old. In other 
cases, the population moves around for family events which may in some 
instances require weeks or months away from homes. Where such mobile 
populations are enrolled into clinical trials there may be difficulty in adhering to 
the follow up period and the protocol. Such issues need to be taken into account 
when planning studies and attempts made to either avoid mobile populations 
where feasible and where it has no impact on generalizability, or factor in 
attrition rates that take this into account. The mobility of populations is critical 
where infectious disease studies are concerned as transmission pattern variations 
can be significant within a short distance. In addition, clear communication lines 
	
	
including the use of mobile phones which are now common place in most 
communities ensure that the team can remain in close contact with participants 
and plan study visits around engagements which were unforeseen or 
undisclosed at the last face to face contact. Setting reasonable visit windows also 
helps to mitigate this risk such that participants have a reasonable window 
within which a visit can be planned. For instance a Day 28 visit could be planned 
to occur anytime between day 21 and day 35. 
 
2.2.7 Stringent Enrolment Criteria: 
Some trials require that stringent inclusion/exclusion criteria be met prior 
to clinical trial participation. A common one is the requirement to have received 
routine infant vaccines within a specified time period often as specified in the 
immunization schedule. This is often a challenge in many parts of the developing 
world as even in countries where immunization coverage is high, the schedule is 
often not well adhered to. Thus there may be several months as opposed to 4 
weeks between vaccine doses. In such instances early planning for the trial may 
involve following up potential participants from birth or even prior to this, to 
ensure that the schedule is adhered to. This definitely comes with a cost and 
where not possible needs to be taken into account in the study design. 
 
2.2.8 Diary Cards: 
The use of diary cards that are completed by the study participants in their 
homes is generally not feasible in vaccine trials in developing countries as in 
many cases the majority of participants are illiterate. An additional complement 
of staff trained to do this will be required who can visit participants homes to fill 
the diary cards. This will increase the cost. In other instances, the involvement of 
the entire household is required such that the literate member can complete the 
card for the mother. Another challenge may arise in this regard when it comes to 
interpretation of trial data as there are likely to be key differences in data 
collected by a primary caregiver such as the mother and that collected by a field 
worker/assistant. For instance mothers may be more likely to report irritability 
in their child than a field assistant would. Additionally as mothers are usually 
resident with their young infants it is easier to take temperatures when the child 
appears warm leading to higher reporting of fever than in the instance where a 
field assistant visits at a certain point in the day when such may not be the case. 
 
2.2.9 Culture/Belief Systems: 
The belief system within a community may pose significant challenges to 
the conduct of clinical trials (Arenas-Lopez et al., 2011). In some instances it is 
difficult to recruit participants with a clear understanding of trial related 
procedures (Louisa et al., 2012). For instance, certain communities believe that 
	
	
blood is sacred and that young children become ill after  venous blood samples 
have been  collected from them (Ota et al., 2012). At best, most mothers know 
only about obtaining blood samples through pin-pricks. These mothers may 
become worried when venous blood samples are collected in clinical trials 
leading to their withdrawing their children from the study, as their initial 
understanding of blood sampling is different from their experience. This is often 
heightened when a study requires the collection of samples into several tubes, 
which can be met with significant resistance due to the perception that this 
implies that more blood is being collected (Howie, 2011). A clear explanation of 
what is to be done with blood samples in different tubes is usually helpful in 
allaying anxiety. In other regions, there is the belief that if a child received oral 
polio vaccines, the child could become sterile and may be infected with HIV. 
Such beliefs would definitely affect the acceptance of clinical trials in that given 
community (Kaufmann & Feldbaum, 2009). As a result, the need for education 
and re-education and the involvement of key community leaders cannot be 
overemphasised. Sponsors as a result need to be flexible in the planning phases 
allowing for long windows for each visit and factoring a significant drop out rate 
into the original sample size estimations. 
The impact of beliefs is not only in those who are uneducated but cuts 
across the board at times and for the educated it gets compounded by the 
information freely available on the internet which can create significant concern 
in reference to certain procedures, research, vaccines and drugs.  
The presence of community advisory boards is crucial in this regard to help the 
study team navigate through wrong perceptions from the community and also 
widely held beliefs that are counterproductive to the research outcomes. This can 
also be allayed by members of the community being investigators which calls for 
capacity building and retention of local expertise in the team for long term 
involvement by the community. There need to be innovate ways to ensure the 
boards remain impartial of the study teams and that they are truly in touch with 
the community perceptions, beliefs, aspirations and changing trends. 
 
2.2.10 Monitoring and Communication: 
Until the mid 1990’s most clinical trials were conducted in Europe, the 
United States and Japan.  Today 10% of all clinical trials occur in Africa 
(Rehnquist, 2001). These trials require conduct to the strictest standards as they 
involve human subjects. The International Conference on Harmonization/ Good 
Clinical Practise (ICH/GCP) guideline is often applied to such research (Englev 
& Petersen, 2003). There are certain procedures, such as reporting serious adverse 
effects etc. that require fast means of communication to the sponsors by either 
telephone or email, which at times unfortunately are either very expensive, 
	
	
dysfunctional or non-existent in rural trial centres. Sponsors need also to be 
aware of these needs and to anticipate them.  
In addition, clear monitoring and communication plans need to be 
communicated and agreed upon before budgets are finalized and signed. This 
has been previously been addressed by use of VISATs in a number of research 
centres and as mobile telephone penetration increases in the region it is becoming 
a major tool for data collection, participant follow up and study team 
communication. This is not without concerns especially as it relates to 
confidentiality.  
Another challenge is that of readily available monitoring teams often 
sourced from Contract Research Organizations (CROs). In many parts of Africa 
however, there is a paucity of such organizations with the few available often 
overwhelmed. This poses a challenge to local institutions to ensure training of 
research managers and auditors so that required personnel is available thus 
making clinical trial monitoring cheaper and more effective in the long run. The 
other challenge is the development of local CROs that understand the regional 
research and cultural dynamics for sustainable capacity development. 
 
2.2.11 Institutional Understanding of Trial Needs: 
As clinical trials are relatively new in certain areas there is often a 
tendency to underestimate the needs of the trial. This may be due to the 
institutions previous experience with basic science and non-interventional 
clinical research which may not have come with the rigors of clinical trials. This 
can lead to significant strain on staff involved in these trials or strain on the 
budget which has not taken all these factors into account. An example is the 
extent of documentation and internal and external quality control needs for 
clinical trials which has serious impact on personnel and infrastructure 
requirements.    
 
2.2.12 Use of Electronic Data Collection (EDC) Methods: 
In many parts of Africa internet facilities are often slow and erratic. Data 
collection is however increasingly based on electronic methods. Where electronic 
case report forms or diaries are used in vaccine trials, this may pose challenges 
for the trials teams when connection speed makes data entry or upload difficult 
or impossible to achieve. In some instances trial sites and indeed the entire 
country have gone without internet access for extended periods of time making it 
impossible to access data real time. In the African context it therefore seems 
pertinent to have in place back-up systems which can be used should the 
electronic systems fail or be temporarily unavailable. The other challenge with 
EDC systems creates a situation where the research centre remains with no data 
copy for their own capacity development once the study is over as the data 
	
	
management has all been done remotely offsite. Study sites need to have clear 
data and material transfer agreements prior to study start. 
 
2.2.13 Vaccine/Sample Storage and Transport: 
Power supply in many parts of Africa remains erratic and unreliable. 
Vaccine trials however require that vaccines can be stored at the required 
temperatures at all times. This often requires a significant investment in vaccine 
fridges with a constant source of power and vaccine carriers as appropriate. The 
need for a stand-by generator which itself has an effective back-up system cannot 
be overemphasised in such situations. Certain study vaccines especially in early 
phase clinical trials require transportation at  20°C or below to the trial site, 
which may not be located at the same site as the storage facility. Unfortunately, 
dry ice is in limited supply in most developing countries. For instance, only one 
company produces dry ice in commercial quantity in The Gambia and this 
supply is often unreliable. Attempts to produce dry ice and liquid nitrogen 
within host institutions are currently not widely available. This suggests the need 
for development of a sustainable “in-house” dry ice and liquid nitrogen 
production in research institutions in developing countries. We also recommend 
development of cold-chain free vaccines where feasible for resource-constrained 
settings. 
Vaccine trials often collect significant quantities of biological samples 
which require storage at specified temperatures until sample analysis is done, or 
the samples are transported to sister laboratories for analysis. Maintaining the 
required temperature for these samples also stresses the need for stand-by 
generators with back-up systems. 
The exploration of solar power as alternative or main source of power with 
the erratic grid power being a back up is important and may be the source of 
power for the future. Sunshine is always available in most parts of sub-Saharan 
Africa and the cost solar power installation has come down remarkably.  
Strathmore University in Nairobi, Kenya has installed solar systems for all its 
power requirements.  
2.2.14 Local Haematology and Biochemical Reference Values: 
In certain parts of Africa there are no local reference values for 
haematology and biochemical parameters for the paediatric age group. 
Haematological and biochemical references are however essential indices used in 
establishing safety parameters, especially in early phase intervention trials 
(Afolabi et al., 2014). The accuracy and appropriateness of these laboratory 
parameters are thus critical to understanding the results from such trials. This 
implies the need to use reference values validated from elsewhere. In view of 
differences in environmental, genetic, and nutritional factors that may influence 
these laboratory indices (Dhingra & Mishra, 2011; Kumwenda et al., 2012), there 
	
	
is a need to ensure the development of local reference values. These values need 
to be developed outside the specific clinical trials to avoid bias. This therefore 
requires specific financial support as part of the holistic development of the 
clinical trial and optimal clinical care framework. 
 
2.2.15 Use of Supplementary EPI Vaccines: 
To ensure adherence to international recommendations aimed at 
facilitating eradication/elimination of childhood vaccine preventable diseases, 
many African countries organize periodic house-to-house campaigns to 
immunize infants under 5 years of age. This is done irrespective of their previous 
receipt of the Expanded Program on Immunization (EPI) vaccines. Notable 
among such campaigns are the polio and measles vaccine campaigns. Among 
infants participating in vaccine trials, these additional immunizations could 
potentially act as confounding variables because of variations in age at 
vaccination and batches of vaccines administered. More important, these 
variations may distort findings about interference of the EPI and study vaccines. 
Studies involving children within age ranges involved in such campaigns need to 
work with EPI teams to devise methods of avoiding such scenarios. This may 
involve placing informative stickers/cards on the child’s immunization record 
(Afolabi et al., 2014) and engaging public health officers and nurses involved in 
these vaccination campaigns to recognise these stickers/cards. The study team 
would then need to ensure all such infants receive all recommended EPI vaccines 
according to local immunization schedules. To further minimize potential 
disruptions in clinical trial schedules, we suggest that the clinical trial team 
should work with the local EPI team to plan and identify favourable dates for the 
supplementary immunizations. In situations where it is impossible to avoid 
study participants or where some of them slip through and get these additional 
vaccines, this needs to be clearly documented and accounted for at the point of 
data analysis. 
 
2.2.16 Analgesics for Post-vaccination Fever: 
A common adverse event following infant vaccinations is fever. Studies 
have shown the efficacy of acetaminophen prophylaxis after whole cell pertussis 
vaccination and also in treating febrile episodes after routine immunizations 
(Dhingra & Mishra, 2011). Some studies have however reported that prophylactic 
or therapeutic use of acetaminophen may reduce immunogenicity to vaccines 
(Prymula et al., 2009; Rose et al., 2013).As such is often encouraged that such 
antipyretics not be used or that use be well documented. In our experience 
however, although mothers reported fever in vaccinated and non-vaccinated 
infants following vaccination, the temperature records taken by trained field staff 
did not support the episodes of reported fever. This observation suggests a need 
	
	
for rational use of acetaminophen after infant vaccinations (Afolabi et al., 2014) 
and may require innovative communication strategies especially in societies 
where such use is generally the norm. 
 
2.2.17 Infants’ Weight Faltering During Follow-up:  
It is common in the developing world for growth to falter characterized 
when complementary feeds are introduced to growing infants (Shields, 
Wacogne, & Wright, 2012). The mothers of infants enrolled in vaccine trials in 
these regions are often educated to use locally available food items as 
complementary diets. However, this does not always result in a change in 
practice and may require intervention of the teams to provide the requisite 
nutrition or monitor the feeding of the child. Sustainability of such interventions 
may be a major financial challenge if not factored into the clinical trial budgets. 
We suggest that clinical trials conducted on children in low-income countries 
make appropriate budgetary provisions for malnutrition-related events that 
commonly occur in this age group (Afolabi et al., 2014). This has recently become 
a major budget line item in a number of clinical trials despite not being foreseen. 
 
2.2.18 Investigator Professional Development: 
Scientific publication is a major parameter for the assessment of 
investigators, but this is unfortunately limited from clinical trials despite the 
huge investment of time and labour. Investigators often do not feel that they are 
getting commiserate scientific output for their intensive input into these trials. In 
some cases the samples are processed in laboratories overseas and with little 
provision for technology transfer and capacity building in country (Louisa et al., 
2012). To be more cost effective, some investigators opt to develop nested studies 
where feasible within the remit of the main vaccine trials. Such studies may entail 
collecting some extra but safe volumes of blood and/or swabs for additional 
analysis at the same time the subjects are sampled for the primary trial.  
Surprisingly, this is often resisted by some trial sponsors no matter how benign 
such an additional study may be to the parent study. We advocate that local 
investigators are allowed to benefit from the clinical trials by technology transfer, 
undertaking nested studies, or funding for relevant higher degrees. These will 
help to place the investigators in a better position to continue to attract funding. 
This is currently changing with some sponsors accepting investigator 
initiated ancillary studies and even providing resources, however, this is an 
exception rather than a norm. There is a need for technology transfer to the 
African centres so that more of the centralised laboratory support can be done in 
the region but this requires proper planning and co-investment by the local 
institutions and their governments in infrastructure development. 
	
	
The support of established investigators to enhance their career and in the 
process mentor upcoming investigators is integral to the future of clinical trials in 
sub-Saharan Africa and requires and formidable partnership between research 
centres, academic institutions, regulatory authorities and relevant governments 
departments. 
 
2.2.19: Changing Dogma on the Need for Accelerated Vaccine Development:  
The development of a vaccine against a particular disease is usually driven 
by potential profits that could be derived from such huge financial investments.  
Very little commercial incentive exists for the pharmaceutical industry to commit 
resources into vaccine development against certain infectious diseases and this 
has contributed to festering of diseases that erupt sporadically in some of the 
poorest parts of Africa. The largest and worst outbreak of Ebola in West Africa 
represents a paradigm shift from this dogma and has dramatically changed 
perceptions about the need for an Ebola vaccine for the affected populations 
(Levine, Tapia, Hill, & Sow, 2014). 
The weak healthcare infrastructure of the affected countries occasioned by 
years of civil wars and political/economic instabilities contributed to the spread 
of the massive outbreak in poor urban slums and remote villages leading to 
nearly 11,000 deaths and 28,000 cases (WHO, 14th January 2016). Healthcare 
workers constituted approximately 10% of the deaths. Consequently, fear for 
their lives and concern for their families led healthcare workers in some settings 
to stay away from their duty posts, while others refused to care for Ebola 
patients. This presented an emergency crisis with multiple dimensions, since 
Ebola has no known cure and no licensed vaccines were available but the 
patients required intensive medical care from clinical staff needed to administer 
this with strict adherence to isolation and infection control techniques (Levine et 
al., 2014). 
The ravaging outbreak showed that Ebola is capable of spreading more 
easily than expected in certain high density impoverished populations. The high 
morbidity and mortality among healthcare workers also revealed a new highly 
focused target population requiring urgent protection from the disease. A well 
tolerated, highly effective Ebola vaccine that can rapidly elicit protection 
following the administration of a single dose would constitute an important 
public health tool (Hoenen, Groseth, & Feldmann, 2012), at the least to protect 
healthcare workers and avoid interruptions in medical care (Kerstiens & 
Matthys, 1999). Subsequently, a vaccine regimen with more durable protection 
can be developed after providing initial prophylactic vaccine for frontline 
workers who are dealing with a dangerous, fast moving virus in remote areas 
with weak health infrastructure (Levine et al., 2014). 
 
	
	
2.2.20 Ethical and Safety Review Process: 
The ethical review process varies from country to country on the continent. 
Given this diversity, there is likely to be significant variation in decisions reached 
following review of the same protocol. The same applies to data safety 
monitoring boards (DSMB) now known as data monitoring committees (DMC) 
which are an essential requirement for vaccine trials. This particularly pertinent 
when considering multicentre studies which are becoming more and more 
common, and suggests a need for some harmonization of standards in this 
regard. This can be achieved through engagement of various stakeholders to 
ensure complementary rather than duplicative roles for the various committees. 
There is also an urgent need to build capacity among members of ethics 
committees ensuring that they are knowledgeable on relevant national and 
international guidelines for vaccine and other clinical research. The AMANET 
network has made an effort to promote health research needs in Africa, by taking 
a holistic approach in addressing human, financial and infrastructural needs at 
research centres. A sub-grant from this group was used by a research institute in 
Tanzania to start a two-way community engagement programme to convey 
information regarding health research ethics to communities. This enhanced 
researchers understanding of community concerns and perceptions of their 
research (Mwangoka et al., 2013). In addition, The European and Developing 
Countries Clinical Trial Partnership (EDCTP) through Mapping of ethics review 
and trial regulatory capacity in sub-Sahara Africa (MARC project) supports 
strengthening of the existing ethical review capacity throughout Africa 
(Mwangoka et al., 2013). 
 
 
 
3. CONCLUSION 
In summary, there are several important reasons for conducting clinical trials of 
investigation products against infectious diseases in developing countries. The 
conduct of these clinical trials have great benefits, pose challenges, as well as 
peculiarities that are worth considering by the investigators, manufacturers, 
funders and sponsors for optimal execution of the trials. Clinical trials in the 
region will have varied costs across the different countries and may cost more. 
This extra cost is however part of the investment for development of the clinical 
trials platform in Africa which has so many facets dictated by rapidly changing 
requirements with the acquisition of new innovations and development of new 
regulations globally.  
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